Silence Therapeutics plc Income Tax Expense Continuing Operations
Silence Therapeutics plc (SLNCF) reported Income Tax Expense Continuing Operations of -GBP 7.04 million for the 12-month period ending 2023-12-31, per its 20-F filed 2024-03-13.
Discontinued › Expense Statement › Income Tax
ifrs-full:IncomeTaxExpenseContinuingOperations · last filed 2024-03-13
| Period end | Income Tax Expense Continuing Operations 12 month |
|---|---|
| 2023-12-31 | -7.04M GBP 20-F · filed 2024-03-13 |
| 2022-12-31 | -6.88M GBP 20-F · filed 2024-03-13 |
| 2021-12-31 | -6.45M GBP 20-F · filed 2024-03-13 |
| 2020-12-31 | -3.49M GBP 20-F · filed 2023-03-15 |
| 2019-12-31 | -3.29M GBP 20-F · filed 2022-03-17 |
| 2018-12-31 | -2.12M GBP 20-F/A · filed 2021-04-29 |